🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Mometasone Furoate Nasal Spray, 50 mcg

    Amneal Pharma Europe Ltd

    Seasonal Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  2. Mometasonfuroaat Teva 50 microgram/verstuiving, neusspray, suspensie, Mometasonfuroat-ratiopharm® 50 Mikrogramm/Sprühstoß Nasenspray, Suspension, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Severe CRSwNP patients with asthma.

    phase 3 small molecule active

    1 trial

  3. Mounjaro 5 mg solution for injection in pre-filled pen, cagrilintide semaglutide, cagrilintide semaglutide, Mounjaro 2.5 mg solution for injection in pre-filled pen, cagrilintide semaglutide

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  4. Multi-centre, Open-label Trial to Assess the SaFety, Pharmacodynamics, Efficacy and Pharmacokinetics of PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease (FLY)

    Chiesi Farmaceutici S.p.A

    Fabry's disease

    phase 3 other active

    1 trial

  5. Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p

    AstraZeneca AB

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  6. N-Acetyl-L-Leucine, granules for suspension

    Intrabio Ireland Limited

    CACNA1A Disorders

    phase 3 small molecule active

    1 trial

  7. N-Acetylcysteine

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathies

    phase 3 small molecule completed

    1 trial

  8. N-Acetylcysteine (NAC) Treatment

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathy

    phase 3 small molecule active

    1 trial

  9. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  10. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  11. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  12. NBI-1117568, NBI-1117568, NBI-1117568 Placebo Capsule

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  13. NBI-74788, Crinecerfont placebo for oral capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  14. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

    phase 3 small molecule terminated

    1 trial

  15. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    2 trials

  16. NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  17. NI-501; emapalumab, NI-501; emapalumab

    Swedish Orphan Biovitrum Pty Ltd

    Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).

    phase 3 small molecule active

    1 trial

  18. NICOPASS 1,5 mg SANS SUCRE MENTHE FRAICHEUR, pastille édulcorée à l'aspartam et à l’acésulfame potassique, V0018 Placebo

    Pierre Fabre Medicament

    Cessation of smoking

    phase 3 small molecule active

    1 trial

  19. NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  20. NIO752, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung

    Novartis Pharmaceuticals

    Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

    phase 3 small molecule active

    1 trial

  21. NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. NKTR-181 BID tablets

    Nektar Therapeutics UK Limited

    Low Back Pain

    phase 3 small molecule completed

    2 trials

  23. NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  24. NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources